{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Melanoma%2C+Metastatic&page=43", "query": { "condition": "Malignant Melanoma, Metastatic", "page": 43 }, "page_size": 10 }, "pagination": { "page": 43, "page_size": 10, "total_count": 1026, "total_pages": 103, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Melanoma%2C+Metastatic&page=44&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Melanoma%2C+Metastatic&page=42&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T20:39:29.520Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01763164", "title": "Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic or Unresectable Cutaneous Melanoma" ], "interventions": [ { "name": "MEK162", "type": "DRUG" }, { "name": "Dacarbazine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 402, "start_date": "2013-07-12", "completion_date": "2019-06-04", "has_results": true, "last_update_posted_date": "2021-03-22", "last_synced_at": "2026-10-16T20:39:29.520Z", "location_count": 77, "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Altamonte Springs, Florida + 46 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Altamonte Springs", "state": "Florida" }, { "city": "Bonita Springs", "state": "Florida" }, { "city": "Bradenton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01763164" }, { "nct_id": "NCT00016055", "title": "Biological Therapy and Temozolomide in Treating Patients With Metastatic Melanoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "lymphokine-activated killer cells", "type": "BIOLOGICAL" }, { "name": "temozolomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "St. Luke's Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2000-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-20", "last_synced_at": "2026-10-16T20:39:29.520Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00016055" }, { "nct_id": "NCT03645928", "title": "Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma", "Squamous Cell Carcinoma of the Head and Neck", "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Lifileucel", "type": "BIOLOGICAL" }, { "name": "LN-145", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "LN-145-S1", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Nivolumab-relatlimab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Iovance Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 225, "start_date": "2019-05-07", "completion_date": "2026-02-20", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-10-16T20:39:29.520Z", "location_count": 20, "location_summary": "La Jolla, California • Los Angeles, California • Denver, Colorado + 15 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03645928" }, { "nct_id": "NCT04955743", "title": "Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Renal Cell Carcinoma", "Brain Metastases", "PD1/PD-L1 Experienced", "Pembrolizumab", "Lenvatinib", "Metastatic Melanoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2022-02-09", "completion_date": "2025-05-28", "has_results": true, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-10-16T20:39:29.520Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04955743" }, { "nct_id": "NCT01352884", "title": "Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "AMP-224", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2011-03", "completion_date": "2014-01", "has_results": false, "last_update_posted_date": "2016-09-05", "last_synced_at": "2026-10-16T20:39:29.520Z", "location_count": 4, "location_summary": "Detroit, Michigan • New York, New York • Huntersville, North Carolina + 1 more", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01352884" }, { "nct_id": "NCT01585415", "title": "Vemurafenib and White Blood Cell Therapy for Advanced Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Cancer", "Melanoma" ], "interventions": [ { "name": "Vemurafenib", "type": "DRUG" }, { "name": "Young TIL", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Aldesleukin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "66 Years", "sex": "ALL", "summary": "18 Years to 66 Years" }, "enrollment_count": 12, "start_date": "2012-04-09", "completion_date": "2016-07-21", "has_results": false, "last_update_posted_date": "2019-11-21", "last_synced_at": "2026-10-16T20:39:29.520Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01585415" }, { "nct_id": "NCT02716948", "title": "SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Malignant Neoplasm in the Brain", "Metastatic Malignant Neoplasm in the Spine", "Stage IV Skin Melanoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Stereotactic Radiosurgery", "type": "RADIATION" } ], "intervention_types": [ "OTHER", "BIOLOGICAL", "RADIATION" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2016-06-23", "completion_date": "2021-08-27", "has_results": false, "last_update_posted_date": "2021-11-30", "last_synced_at": "2026-10-16T20:39:29.520Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02716948" }, { "nct_id": "NCT00553306", "title": "Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Melanoma", "Stage IV Melanoma" ], "interventions": [ { "name": "therapeutic autologous lymphocytes", "type": "BIOLOGICAL" }, { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "biopsy", "type": "PROCEDURE" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "polymerase chain reaction", "type": "GENETIC" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "OTHER", "GENETIC" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 10, "start_date": "2007-09", "completion_date": "2012-03", "has_results": false, "last_update_posted_date": "2017-02-15", "last_synced_at": "2026-10-16T20:39:29.520Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00553306" }, { "nct_id": "NCT00704938", "title": "Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer", "Melanoma (Skin)", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "anti-p53 T-cell receptor-transduced peripheral blood lymphocytes", "type": "BIOLOGICAL" }, { "name": "autologous dendritic cell-adenovirus p53 vaccine", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2008-06", "completion_date": "2009-08", "has_results": true, "last_update_posted_date": "2015-10-28", "last_synced_at": "2026-10-16T20:39:29.520Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00704938" }, { "nct_id": "NCT00314106", "title": "Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "Melanoma Reactive TIL", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "IL-2", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "1200 total body irradiation (TBI)", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2006-04", "completion_date": "2009-03", "has_results": true, "last_update_posted_date": "2012-10-18", "last_synced_at": "2026-10-16T20:39:29.520Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00314106" } ] }